AB0817 CAN STATINES IMPROVE BONE QUALITY IN POSMENOPAUSAL OSTEOPOROSIS?
Authors: Pablo Astesana, Paula Alba, Carla Gobbi, Ruth Fernandez, Eduardo Albiero, Marcelo Yorio
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Osteoporosis (OP) is the most frequent metabolic bone disease. It has low bone mass and microarchitectural deterioration, which increases the risk of fractures. The most commonly used drugs are bisphosphonates, however statins (ST) have pleiotropic properties, and some researchers suggested their use in OP. <h3>Objectives</h3> To determine the effect of ST on bone mineral density (BMD) in postmenopausal osteoporotic women. <h3>Methods</h3> A cross-sectional study, control case where postmenopausal women with hypercholesterolemia treated with ST for a period not less than 6 months were studied for two years. The control group was postmenopausal population that did not receive statins. Exclusion criteria: Diabetes, previous treatment with estrogen, calcitonin, anabolic, steroids, bisphosphonates or vitamin D during a period of 6 months prior to enter to the study or with amenorrhea less than 12 months. We evaluated age, weight, height, BMI, personal and first degree family members' history of fracture, use of corticosteroids, smoking, alcoholism, daily calcium intake, sedentary lifestyle, phosphocalcic metabolism laboratory and Vitamin D. All patients were performed Bone Densitometry by dual-energy X-ray absorptiometry (DXA) with an Hologic equipment in right hip and lumbar spine, staging them according to WHO. The statistical analysis was performed using the Student's test and the Fisher test for categorical variables. Values of p less than 0.05 were considered significant. <h3>Results</h3> 202 patients were enrolled in the ST group and 203 in the control group. Age, weight, height and BMI were 62.54; 69.6; 1.60 and 27.1 in the ST group and 58.5; 65.7; 1.59 and 26.83 in the control group respectively (p = 0.000, p = 0.001 p = 0.79, p = 0.38). There were no significant differences in risk factors for OP between groups. The average lumbar BMD was -0.87 for the ST group and -1.76 for the control group (p = 0.000), the average femur neck BMD was -1.15 for the ST group and -1.56 for control ( p = 0.000), the total hip BMD was -0.32 for the ST group and -0.74 for the control group (p = 0.001), vitamin D was 25.57 for the ST group and 27.71 (p = 0.120). <h3>Conclusion</h3> ST can improve Bone Mineral Density in postmenopausal women, more studies are needed to confirm these results. <h3>References</h3> [1] Pacheco-Pantoja EL, Alvarez-Nemegyei J. Statins and osteoporosis: a latent promise. Reumatol Clin. 2014 Jul-Aug;10(4):201-3. doi: 10.1016/j.reuma.2014.04.005. [2] An T1, Hao J2, Sun S1, Li R1, Yang M1, Cheng G3, Zou M4. Efficacy of statins for osteoporosis: a systematic review and meta-analysis. Osteoporos Int. 2017Jan;28(1):47-57. doi: 10.1007/s00198-016-3844-8. [3] Kaleağasıoğlu F, Olcay E, Onur R. Statins as potential agents for the prevention and treatment of osteoporosis. Endocrine. 2018Oct;62(1):269. doi: 10.1007/s12020-018-1650-0. Epub 2018 Jun 17. [4] Horiuchi N, Maeda T. Statins and bone metabolism. Oral Dis. 2006Mar;12(2):85-101. Review. <h3>Disclosure of Interests</h3> Pablo Astesana: None declared, Paula Alba Speakers bureau: Glaxo, Jannsen, Carla Gobbi Speakers bureau: Pfizer, Monteverde, Ruth Fernandez: None declared, Eduardo Albiero: None declared, Marcelo Yorio: None declared